Uncategorized
New Data Reinforce the Relationship Between B-Cell Depletion and Improved Outcomes in People Receiving UPLIZNA® (inebilizumab-cdon) for Neuromyelitis Optica Spectrum Disorder (NMOSD)
DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics announced results from a new analysis of UPLIZNA® (inebilizumab-cdon) in neuromyelitis optica spectrum disorder (NMOSD).